CN111419837B - Use of 12 alpha-methoxy-germacrane-triene-12, 6 alpha-acetal for anti-human rhabdomyosarcoma - Google Patents
Use of 12 alpha-methoxy-germacrane-triene-12, 6 alpha-acetal for anti-human rhabdomyosarcoma Download PDFInfo
- Publication number
- CN111419837B CN111419837B CN202010374927.7A CN202010374927A CN111419837B CN 111419837 B CN111419837 B CN 111419837B CN 202010374927 A CN202010374927 A CN 202010374927A CN 111419837 B CN111419837 B CN 111419837B
- Authority
- CN
- China
- Prior art keywords
- alpha
- human
- germacrane
- triene
- acetal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Physical Education & Sports Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention discloses an application of 12 alpha-methoxy-germacrane-triene-12, 6 alpha-acetal in resisting human rhabdomyosarcoma. The invention discovers that 12 alpha-methoxy-germacrane-1 (10), 4,11 (13) -triene-12, 6 alpha-acetal has obvious inhibition effect on proliferation of human breast cancer MCF-7 cell strain, human glioma U87 cell strain and human rhabdomyosarcoma RD cell strain, and has a prospect of developing drugs for resisting human breast cancer, human glioma or human rhabdomyosarcoma.
Description
Technical Field
The invention relates to the field of medicines, in particular to an application of 12 alpha-methoxy-germacrane-1 (10), 4,11 (13) -triene-12, 6 alpha-acetal in resisting human rhabdomyosarcoma.
Background
Cancer is one of the major diseases and serious public health problems that seriously threaten human survival and social development, and cancer control has become the key point of the health strategy of governments around the world. In recent years, with global economic development, population aging, lifestyle changes and ecological environment changes, the morbidity and mortality of cancer are on the rise as a whole, and the burden of cancer is increasing.
Human rhabdomyosarcoma is a malignant tumor that originates in striated muscle cells or mesenchymal cells that differentiate into striated muscle cells, and is the most common one of childhood soft tissue sarcomas. The incidence rate of the human rhabdomyosarcoma is second to that of malignant fibrous histiocytoma and liposarcoma, and the human rhabdomyosarcoma occupies the third place of soft tissue sarcoma, thereby seriously threatening the human health. Currently, the treatment of human rhabdomyosarcoma remains one of the major challenges in the tumor field, and therefore, the search for effective therapeutic drugs is particularly urgent.
Disclosure of Invention
The invention aims to provide the application of 12 alpha-methoxy-germacrane-1 (10), 4,11 (13) -triene-12, 6 alpha-acetal in resisting human rhabdomyosarcoma.
The technical scheme for realizing the purpose is as follows:
the medical use of 12 alpha-methoxy-germacrane-1 (10), 4,11 (13) -triene-12, 6 alpha-acetal for preparing a medicament for treating human rhabdomyosarcoma, the chemical structural formula of which is as follows:
a medicine for resisting human rhabdomyosarcoma contains 12 alpha-methoxy-germacrane-1 (10), 4,11 (13) -triene-12, 6 alpha-acetal as active component, and pharmaceutically acceptable adjuvants.
Preferably, the adjuvant may be a solid adjuvant or a liquid adjuvant.
Preferably, the dosage form can be tablets, capsules, granules and injections.
Has the advantages that:
the invention discovers that 12 alpha-methoxy-germacrane-1 (10), 4,11 (13) -triene-12, 6 alpha-acetal has obvious inhibition effect on proliferation of human breast cancer MCF-7 cell strain, human glioma U87 cell strain and human rhabdomyosarcoma RD cell strain, and has a prospect of developing drugs for resisting human breast cancer, human glioma or human rhabdomyosarcoma.
Drawings
FIG. 1 is a chemical structural formula of 12 α -methoxy-germacrane-1 (10), 4,11 (13) -triene-12, 6 α -acetal;
FIG. 2 shows the anti-tumor profile of 12 α -methoxy-germacrane-1 (10), 4,11 (13) -triene-12, 6 α -acetal against 4 tumor cells.
Detailed Description
1. Test materials
Human breast cancer MCF-7 cell line, human acute myelogenous leukemia MV4-11 cell line, human glioma U87 cell line and human rhabdomyosarcoma RD cell line were purchased from American ATCC company and frozen in liquid nitrogen.
The purity of 12 alpha-methoxy-germacrane-1 (10), 4,11 (13) -triene-12, 6 alpha-acetal is not lower than 98%, the structural formula is shown in figure 1, and the pharmaceutical solution is prepared for standby.
RPMI1640 medium, DMEM medium, fetal bovine serum were purchased from Gibco.
Penicillin, streptomycin was purchased from Sigma.
The CCK8 detection kit is purchased from Nanjing Biyunnan biology.
2. Test method
1. Cell culture
Recovering human breast cancer MCF-7 cell line frozen with liquid nitrogen according to conventional method, suspension culturing in DMEM culture solution containing 10% fetal calf serum, 100U/ml penicillin, and 100 μ g/ml streptomycin, and making CO 5% at 37 deg.C 2 And culturing in a constant-temperature incubator with saturated humidity, changing liquid for passage every 2-3 d, and taking the cells in logarithmic growth phase for experiment.
Recovering human acute myelogenous leukemia MV4-11 cell line frozen in liquid nitrogen according to conventional method, suspension culturing in RPMI1640 culture solution containing 10% fetal calf serum, 100U/ml penicillin and 100. Mu.g/ml streptomycin, and making the cell line at 37 deg.C and 5% CO 2 And culturing in a constant-temperature incubator with saturated humidity, changing liquid for passage every 2-3 d, and taking the cells in logarithmic growth phase for experiment.
Resuscitating human glioma U87 cell line frozen by liquid nitrogen by conventional method, suspension culturing in DMEM culture solution containing 10% fetal calf serum, 100U/ml penicillin, and 100. Mu.g/ml streptomycin, at 37 deg.C, 5% 2 And culturing in a constant-temperature incubator with saturated humidity, changing liquid every 2-3 days for passage, and taking cells in logarithmic growth phase for experiment.
Resuscitating the human rhabdomyosarcoma RD cell line frozen by liquid nitrogen according to conventional method, suspension culturing in DMEM culture solution containing 10% fetal calf serum, 100U/ml penicillin, and 100. Mu.g/ml streptomycin, at 37 deg.C, 5% 2 And culturing in a constant-temperature incubator with saturated humidity, changing liquid for passage every 2-3 d, and taking the cells in logarithmic growth phase for experiment.
2. CCK8 method for determining proliferation inhibition effect of drug on MV4-11 cells
Taking each tumor cell in logarithmic growth phase, digesting and re-suspending to prepare the tumor cell with the density of 1.5 multiplied by 10 5 The cell suspension/mL is inoculated into 96-well plate according to the inoculation amount of 90 μ L per well, 10 μ L of drug solution with different concentrations is added, each concentration is provided with 3 multiple wells, the cells cultured without adding drugs are used as a control group, the culture solution without cells is used as a blank group, and the blank group is placed at 37 ℃ and 5%CO 2 Culturing in a constant temperature incubator with saturated humidity for 48h, adding 10 mu L of CCK8 reagent into each hole, incubating for 4h, measuring the OD450 value of each hole at the wavelength of 450nm of an enzyme linked immunosorbent assay (ELISA) detector, taking the average value of 3 holes, measuring the proliferation inhibition rate according to the following formula and calculating the IC50 value. Three were run in parallel.
Proliferation inhibition (%) = [1- (OD drug group-OD blank)/(OD control group-OD blank) ] × 100%.
3. Statistical analysis
Software SPSS17.0 is adopted for statistical analysis processing, the metering data is expressed by mean +/-standard deviation, t test is adopted for comparison among groups, variance analysis is adopted for comparison among groups, and the difference P < 0.05 has statistical significance.
3. Test results
The IC50 values of the inhibition effects of 12 α -methoxy-germacrane-1 (10), 4,11 (13) -triene-12, 6 α -acetal on the proliferation of various tumor cells are shown in table 1, and it can be seen from table 1 that 12 α -methoxy-germacrane-1 (10), 4,11 (13) -triene-12, 6 α -acetal all have excellent inhibition effects on the proliferation of human breast cancer MCF-7 cell line, human glioma U87 cell line and human rhabdomyosarcoma RD cell line, and have no significant inhibition effect on the proliferation of human acute myelogenous leukemia MV4-11 cell line.
TABLE 1 IC50 values of 12 α -methoxy-germacrane-1 (10), 4,11 (13) -triene-12, 6 α -acetal on 4 tumor cells
FIG. 2 is a graph of the anti-tumor profile of 12 α -methoxy-germacrane-1 (10), 4,11 (13) -triene-12, 6 α -acetal against 4 tumor cells tested. The anti-tumor spectrum shows that the 12 alpha-methoxy-germacrane-1 (10), 4,11 (13) -triene-12, 6 alpha-acetal has obvious inhibition effect on the proliferation of human breast cancer MCF-7 cell strains, human glioma U87 cell strains and human rhabdomyosarcoma RD cell strains, and has the prospect of developing drugs for resisting human breast cancer, human glioma or human rhabdomyosarcoma.
Claims (1)
- The medical use of 12 α -methoxy-germacrane-1 (10), 4,11 (13) -triene-12, 6 α -acetal for the preparation of a medicament against rhabdomyosarcoma, the chemical structure of 12 α -methoxy-germacrane-1 (10), 4,11 (13) -triene-12, 6 α -acetal being as follows:
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010374927.7A CN111419837B (en) | 2020-05-07 | 2020-05-07 | Use of 12 alpha-methoxy-germacrane-triene-12, 6 alpha-acetal for anti-human rhabdomyosarcoma |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010374927.7A CN111419837B (en) | 2020-05-07 | 2020-05-07 | Use of 12 alpha-methoxy-germacrane-triene-12, 6 alpha-acetal for anti-human rhabdomyosarcoma |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN111419837A CN111419837A (en) | 2020-07-17 |
| CN111419837B true CN111419837B (en) | 2023-03-03 |
Family
ID=71550590
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010374927.7A Active CN111419837B (en) | 2020-05-07 | 2020-05-07 | Use of 12 alpha-methoxy-germacrane-triene-12, 6 alpha-acetal for anti-human rhabdomyosarcoma |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111419837B (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107737103A (en) * | 2017-12-18 | 2018-02-27 | 张欣 | A kind of intratumor injection liquid for being used to treat rhabdomyosarcoma |
-
2020
- 2020-05-07 CN CN202010374927.7A patent/CN111419837B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107737103A (en) * | 2017-12-18 | 2018-02-27 | 张欣 | A kind of intratumor injection liquid for being used to treat rhabdomyosarcoma |
Non-Patent Citations (1)
| Title |
|---|
| Bio-Assay Guided Isolation of Germacranes with Anti-Protozoan Activity from Magnolia sororum;Luis A. Sánchez;《Natural Product Communications》;20071231;第2卷(第11期);第1065-1069页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN111419837A (en) | 2020-07-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11117919B2 (en) | Icariside compound, preparation method thereof, and application thereof | |
| CN102614170A (en) | Application of artemisinin B in preparation of antitumor drugs | |
| CN111419837B (en) | Use of 12 alpha-methoxy-germacrane-triene-12, 6 alpha-acetal for anti-human rhabdomyosarcoma | |
| CN111499649B (en) | Benzodifuranone compound with anti-tumor activity, preparation method and application thereof | |
| CN101352448B (en) | Use of Liriope muscari Bailey C in pharmacy | |
| CN111329855B (en) | Application of 12 alpha-methoxy-germacrane-triene-12, 6 alpha-acetal in resisting human breast cancer | |
| CN111419836B (en) | Use of 12 alpha-methoxy-germacrane-triene-12, 6 alpha-acetal for combating human gliomas | |
| CN109833321A (en) | It is a kind of to reverse liver cancer cells to the pharmaceutical composition of sorafenib drug resistance | |
| CN111743909B (en) | Use of smilacin A for treating rhabdomyosarcoma | |
| CN109364045B (en) | Heat shock protein 90 inhibitor and application thereof in liver cancer treatment | |
| CN102836151A (en) | Application of Brevilin A when serving as JAK-STATs signal target inhibitor | |
| CN111374979A (en) | Medical application of compound in treatment of oral cancer by inducing apoptosis of oral cancer cells | |
| CN115645416B (en) | Application of Calvasterol A in preparation of medicines for treating hepatic fibrosis | |
| CN113133994B (en) | Application of tricyclic diterpene natural product Vinigrol or pharmaceutical composition thereof in preparation of anti-cancer drugs | |
| CN111450096B (en) | Application of phosphorylation inhibitor of STAT3 in preparation of medicine for resisting acute myeloid leukemia | |
| CN115645382A (en) | Application of compound tetrahydromagnol in preparation of medicine for treating gastric cancer | |
| CN111529531B (en) | STAT3 phosphorylation inhibitor and application thereof in preparing medicine for treating acute myeloid leukemia | |
| CN111281870B (en) | Medicine for inhibiting invasion and metastasis of oral cancer cells | |
| CN115364076A (en) | Application of diterpenoid compound DB-022133 in preparation of medicine for treating gastric cancer | |
| CN102008493A (en) | Application of panaxadiol saponin in preparing medicines combined with glucocorticoid receptor | |
| CN109602775B (en) | Application of chicory alcohol extract in preparation of anti-breast cancer drugs | |
| CN112294967A (en) | Application of mTOR inhibitor and anticancer drug | |
| Wang et al. | Molecular Mechanism of Induction on Apoptosis of Human Esophageal Cancer HCE-4 Cells by Active Components from Astragalus mernbranaceus | |
| CN113908168A (en) | Application of pectolinarin in preparing anti-osteosarcoma medicine and anti-osteosarcoma medicinal preparation | |
| CN112438986A (en) | Application of losartan potassium and dacarbazine combined medicine in preparation of medicine for treating intestinal cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| TA01 | Transfer of patent application right | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20221116 Address after: 100,096 401-406, Floor 4, Building 10, Zone 1, Yard 8, Shengshengyuan Road, Zhongguancun Life Science Park, Huilongguan Town, Changping District, Beijing Applicant after: BEI ZHENG STEM CELLS BIOLOGICAL TECHNOLOGY CO.,LTD. (BEIJING) Address before: 211199 Jiangning high tech park, No.42, Xingmin North Road, Jiangning District, Nanjing City, Jiangsu Province Applicant before: Nanjing saierjian Biotechnology Co.,Ltd. |
|
| CB02 | Change of applicant information | ||
| CB02 | Change of applicant information |
Address after: 100,096 401-406, Floor 4, Building 10, Zone 1, Yard 8, Shengshengyuan Road, Zhongguancun Life Science Park, Huilongguan Town, Changping District, Beijing Applicant after: BEI ZHENG STEM CELLS BIOLOGICAL TECHNOLOGY CO.,LTD. (BEIJING) Address before: 100,096 401-406, Floor 4, Building 10, Zone 1, Yard 8, Shengshengyuan Road, Zhongguancun Life Science Park, Huilongguan Town, Changping District, Beijing Applicant before: BEI ZHENG STEM CELLS BIOLOGICAL TECHNOLOGY CO.,LTD. (BEIJING) |
|
| GR01 | Patent grant | ||
| GR01 | Patent grant |